Lincomycin inhibits bacterial protein synthesis in swine by binding to the 50S ribosomal subunit. This binding prevents the translocation step, halting the addition of amino acids to the growing polypeptide chain. Consequently, bacterial protein synthesis ceases, leading to bacterial cell death.
Target Bacteria
Lincomycin primarily targets Gram-positive bacteria, including Staphylococcus, Streptococcus, and Clostridium species, frequently causing infections in swine. Its activity against Gram-negative bacteria is limited.
Pharmacokinetics in Swine
Following oral administration, lincomycin is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations are usually reached within 1-2 hours. Lincomycin is widely distributed throughout the body, including tissues relevant to swine infections. Excretion is primarily through urine and feces.
Important Considerations
Always adhere to recommended dosages and treatment durations. Monitor animals for adverse effects, which can include gastrointestinal upset. Develop a comprehensive treatment plan with a veterinarian. Appropriate antibiotic stewardship is vital for minimizing the risk of antibiotic resistance. Use lincomycin only when necessary, considering alternative treatments when appropriate.
